Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
On Monday, Tempus AI, Inc.
(NASDAQ:TEM) agreed to acquire Personalis, Inc.
(NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities.
Tempus AI shares erased early losses and recovered after an initial selloff tied to the company's acquisition of Personalis.
Tempus AI Targets $20 Billion MRD Market The acquisition, valued at $1.5 billion, is set to expand Tempus' reach in the MRD market.
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies…
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
Tempus AI acquires Personalis for $1.5 billion to expand cancer MRD testing capabilities, targeting a $20 billion market with…
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Discover why Tempus AI Inc (NASDAQ:TEM) stock is surging today following major platform expansions and landmark clinical data…
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in…
